Geode Capital Management LLC Has $32.54 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Geode Capital Management LLC raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,448,040 shares of the company's stock after buying an additional 126,306 shares during the quarter. Geode Capital Management LLC owned 2.04% of Nurix Therapeutics worth $32,544,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Nurix Therapeutics during the third quarter worth about $346,000. EP Wealth Advisors LLC bought a new position in shares of Nurix Therapeutics during the 3rd quarter valued at about $240,000. Wellington Management Group LLP lifted its holdings in shares of Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after purchasing an additional 280,240 shares in the last quarter. Finally, Quarry LP grew its position in shares of Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $56,000 after purchasing an additional 2,435 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NRIX. HC Wainwright lifted their price target on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Oppenheimer upped their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 4th. BTIG Research initiated coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price target on the stock. Royal Bank of Canada cut their price target on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a report on Monday, October 14th. Finally, Stephens reiterated an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $30.35.

Nurix Therapeutics Trading Up 1.8 %

Shares of NASDAQ:NRIX traded up $0.36 during trading on Thursday, reaching $19.93. 454,897 shares of the stock were exchanged, compared to its average volume of 905,871. The firm has a market cap of $1.41 billion, a PE ratio of -6.85 and a beta of 2.12. Nurix Therapeutics, Inc. has a 12 month low of $7.65 and a 12 month high of $29.56. The stock has a 50-day moving average price of $23.03 and a 200-day moving average price of $22.39.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 2,368 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares in the company, valued at approximately $905,661. This trade represents a 5.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christine Ring sold 5,760 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company's stock, valued at approximately $546,680.16. This trade represents a 18.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,401 shares of company stock worth $437,453 in the last quarter. Corporate insiders own 9.80% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.